Abbott Laboratories (ABT) : Chicago Trust Co Na reduced its stake in Abbott Laboratories by 16.42% during the most recent quarter end. The investment management company now holds a total of 126,074 shares of Abbott Laboratories which is valued at $5,189,206 after selling 24,769 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Abbott Laboratories makes up approximately 2.39% of Chicago Trust Co Na’s portfolio.
Other Hedge Funds, Including , Nisa Investment Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 10,822 additional shares and now holds a total of 529,625 shares of Abbott Laboratories which is valued at $21,799,365. Abbott Laboratories makes up approx 0.29% of Nisa Investment Advisors’s portfolio.Gradient Investments reduced its stake in ABT by selling 109,203 shares or 97.94% in the most recent quarter. The Hedge Fund company now holds 2,296 shares of ABT which is valued at $99,876. Abbott Laboratories makes up approx 0.01% of Gradient Investments’s portfolio.Vontobel Asset Management Inc reduced its stake in ABT by selling 16,996 shares or 0.37% in the most recent quarter. The Hedge Fund company now holds 4,537,309 shares of ABT which is valued at $197,372,942. Abbott Laboratories makes up approx 1.57% of Vontobel Asset Management Inc’s portfolio.Ronna Sue Cohen boosted its stake in ABT in the latest quarter, The investment management firm added 1,460 additional shares and now holds a total of 90,754 shares of Abbott Laboratories which is valued at $3,947,799. Abbott Laboratories makes up approx 2.99% of Ronna Sue Cohen’s portfolio.Academy Capital Management Inctx reduced its stake in ABT by selling 96 shares or 0.07% in the most recent quarter. The Hedge Fund company now holds 139,395 shares of ABT which is valued at $5,989,803. Abbott Laboratories makes up approx 1.60% of Academy Capital Management Inctx’s portfolio.
Abbott Laboratories closed down -2.34 points or -5.38% at $41.16 with 2,38,96,101 shares getting traded on Tuesday. Post opening the session at $43.2, the shares hit an intraday low of $41.02 and an intraday high of $43.27 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.